SUONET 2017 - 18th Annual Meeting of the Society of Urologic Oncology
Nov 28 - Dec 02, 2017 | Washington, DCUS
LARVOL is not affiliated with 18th Annual Meeting of the Society of Urologic Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 5 abstracts linked to Trials
A PHASE 3 TRIAL TO COMPARE EFFICACY AND SAFETY OF LENVATINIB IN COMBINATION WITH EVEROLIMUS OR PEMBROLIZUMAB VS SUNITINIB ALONE IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
KEYNOTE-564: PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PEMBROLIZUMAB AS ADJUVANT TREATMENT FOR RENAL CELL CARCINOMA
SURVIVAL OUTCOMES FOR AFRICAN-AMERICAN (AA) VERSUS MATCHED CAUCASIAN (CAU) PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH SIPULEUCEL-T.
SURVIVAL OUTCOMES FOR AFRICAN-AMERICAN (AA) VERSUS MATCHED CAUCASIAN (CAU) PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH SIPULEUCEL-T.
KEYNOTE-564: PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PEMBROLIZUMAB AS ADJUVANT TREATMENT FOR RENAL CELL CARCINOMA